With our in vitro studies showing increased sensitivity of HPV+ HNSCC cells to PARP inhibition, we next validated these findings in vivo by assessing tumor growth rate in mice bearing HPV+ HNSCC xenografts. Here, PARP1 is linked to head and neck squamous cell carcinoma.